Capricor Therapeutics, Inc.CAPRNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank41
3Y CAGR-42.6%
5Y CAGR-35.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-42.6%/yr
vs -2.2%/yr prior
5Y CAGR
-35.2%/yr
Recent deceleration
Acceleration
-40.4pp
Decelerating
Percentile
P41
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.69% |
| Q3 2025 | 4.46% |
| Q2 2025 | -6.52% |
| Q1 2025 | 41.98% |
| Q4 2024 | 23.38% |
| Q3 2024 | 13.27% |
| Q2 2024 | -24.90% |
| Q1 2024 | 18.74% |
| Q4 2023 | 17.93% |
| Q3 2023 | 5.74% |
| Q2 2023 | -19.53% |
| Q1 2023 | 22.30% |
| Q4 2022 | 8.95% |
| Q3 2022 | 8.84% |
| Q2 2022 | -13.22% |
| Q1 2022 | 28.34% |
| Q4 2021 | 17.52% |
| Q3 2021 | 0.60% |
| Q2 2021 | -6.07% |
| Q1 2021 | 27.61% |
| Q4 2020 | 14.72% |
| Q3 2020 | -19.16% |
| Q2 2020 | 41.49% |
| Q1 2020 | 29.81% |
| Q4 2019 | -3.87% |
| Q3 2019 | 9.62% |
| Q2 2019 | -14.80% |
| Q1 2019 | -11.63% |
| Q4 2018 | -12.23% |
| Q3 2018 | 6.88% |
| Q2 2018 | -15.25% |
| Q1 2018 | 12.28% |
| Q4 2017 | 13.68% |
| Q3 2017 | -12.67% |
| Q2 2017 | 4.88% |
| Q1 2017 | 3.03% |
| Q4 2016 | -8.41% |
| Q3 2016 | -12.13% |
| Q2 2016 | 32.17% |
| Q1 2016 | 0.65% |